| |||||||||
| Login :: Register :: Search forums :: Top Users :: Reagent |
|
Position: Discussion forums > Bioscience biotechniques discussion forums > Proteomics and protein biochemistry forum
|
EGFR
Posted by: Zorro (IP Hidden, New member, 4)
Date: June 10, 2005 06:08AM
hi
i am not sure whether this the right place to post this,, anyway its a simple question.. Are EGFR--Epidermal growth factor receptors different for different cells i.e. for brain ,lung , kidney etc....if so how are they different
Re: EGFR
Posted by: 5'-ATCG (IP Hidden, Unregistered user, )
Date: June 10, 2005 03:15PM
There are different subtypes of EGF receptor: EGF receptor subtype 1 (HER1), EGF receptor subtype neu (HER2), EGF receptor subtype Erb-3 (HER3)....All depends on the distribution of these receptors on your cells. Different cell types ahve different distribution.
Re: EGFR
Posted by: Zorro (IP Hidden, New member, 4)
Date: June 11, 2005 04:14AM
Thanks for the reply. Anway i was studying the effects of erlotinib on Brain cancer,and its a EGFR tyrosine kinase inhibitor. So what i wanted to know is that, are these subtypes distributed randomly on cell surface,, or say a particular type found on one particular cell.
Re: EGFR
Posted by: 5'-ATCG (IP Hidden, Unregistered user, )
Date: June 12, 2005 12:55AM
I guess your brain tumor is glioblastoma? and erlotinib is not a pan EGFR inhibitor but targets a particular subtype?
If so, you need to check the literature if glioblastome express evenly these subtypes or overexpress a particular subtype. If there is no report before, you can determine yourself by overexpressing a particular subtype and see if it can potentiate erlotinib effect.
Re: EGFR
Posted by: Zorro (IP Hidden, New member, 4)
Date: June 20, 2005 06:34AM
EGFR is part of a subfamily of four closely related receptors EGFR (or ErbB-1), Her 2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4), in the case of glioblastoma , what i was able to see was the over expression of EGFR. Others are also over expressed i.e. Her-2 over expression leaded to higher mortality rate. i didn't see a specificity for erlotinib to any other subtype, so i think that its mainly against EGFR,binds on the ATP binding cleft of EGFR.
|
We are moving ... Please post to our new community forums
|
|
||||||||